Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Change in Account Payables (2019 - 2025)

Summit Therapeutics (SMMT) has disclosed Change in Account Payables for 7 consecutive years, with -$2.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 240.29% year-over-year to -$2.1 million, compared with a TTM value of $15.3 million through Dec 2025, up 659.45%, and an annual FY2025 reading of $15.3 million, up 659.45% over the prior year.
  • Change in Account Payables was -$2.1 million for Q4 2025 at Summit Therapeutics, down from -$839000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $17.9 million in Q2 2025 and bottomed at -$3.5 million in Q2 2022.
  • Average Change in Account Payables over 5 years is $686900.0, with a median of -$426500.0 recorded in 2023.
  • Peak annual rise in Change in Account Payables hit 1102.6% in 2024, while the deepest fall reached 1122.56% in 2024.
  • Year by year, Change in Account Payables stood at -$1.4 million in 2021, then plummeted by 73.68% to -$2.4 million in 2022, then surged by 71.63% to -$672000.0 in 2023, then soared by 327.53% to $1.5 million in 2024, then crashed by 240.29% to -$2.1 million in 2025.
  • Business Quant data shows Change in Account Payables for SMMT at -$2.1 million in Q4 2025, -$839000.0 in Q3 2025, and $17.9 million in Q2 2025.